Monday, March 2, 2026

medac appoints Dr. Christoph Willers as Chief Scientific Officer

The medac Group has appointed Dr. Christoph Willers as Chief Scientific Officer (CSO). With the appointment, the company has completed a reshuffle of its Management Board and is strengthening science and development at leadership level.

Responsibility for R&D, studies, and portfolio steering

As CSO, Willers will be responsible for research, preclinical and clinical development, clinical studies, as well as pipeline and portfolio management. The company’s stated aim is to align R&D more consistently with medical need and to further reinforce scientific excellence.

Emphasis on clinical research and evidence-based innovation

medac also links the CSO role to the targeted development of its scientific foundation. In addition to continuously improving existing therapies, the company intends to put greater focus on new scientific approaches, evidence-based enhancements, and clinical research, especially where a clear medical benefit is expected.

Experience in building and transforming capabilities

According to the company, Willers brings many years of experience in leading scientific organizations and in building and transforming development and manufacturing capacities. medac highlights the combination of medical training, scientific expertise, and management experience.

With the appointment, the company aims to further expand its scientific capabilities, with the goal of making medically necessary therapies available and improving patients’ quality of life worldwide.